DOCSLIB.ORG

Protein–Protein Interactions in Drug Discovery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein–Protein Interactions in Drug Discovery 56 Methods and Principles in Medicinal Chemistry Dömling Edited by Alexander Dömling Treating protein-protein interactions as a novel and highly promising class of drug targets, this volume introduces the underlying strategies step by step, from the biology of PPIs to biophysical and computational methods for their investigation. (Ed.) The main part of the book describes examples of protein targets for which small molecule modulators have been developed, covering such Protein–Protein diverse fields as cancer, autoimmune disorders and infectious diseases. Tailor-made for the practicing medicinal chemist, this ready reference includes a wide selection of case studies taken straight from the develop- ment pipeline of major pharmaceutical companies to illustrate the power Interactions in and potential of this approach. From the contents: G Prediction of intra- and inter-species protein-protein interactions Drug Discovery facilitating systems biology studies G Modulators of protein-protein interactions: the importance of three-dimensionality G Interactive technologies for leveraging the known chemistry of anchor residues G SH3 domains as drug targets G P53 MDM2 antagonists: towards non genotoxic anticancer Protein–Protein Interactions treatments in Drug Discovery Volume 56 G Inhibition of LFA-1/ICAM interaction for treatment of autoimmune diseases G The PIF-binding pocket of AGC kinases Series Editors: G Peptidic inhibitors of protein-protein interactions for cell adhesion R.Mannhold, receptors G The REPLACE strategy for generating non-ATP competitive H.Kubinyi, inhibitors of cell-cycle protein kinases G.Folkers and more Alexander Dömling studied Chemistry and Biology at the Technical University Munich, Germany. After obtaining his PhD under the supervision of Ivar Ugi, he spent a postdoctoral year at the Scripps Research Institute in La Jolla (USA) in the group of Nobel Laureate Barry Sharpless. In 2004 he performed his habilitation at the Technical University of Munich. Since 2006 he teaches and performs research at the University of Pittsburgh in the Department of Pharmacy with secondary appointments in Chemistry and Computational Biology. In 2010 he became full professor receiving his tenure in Pittsburgh. Since 2011 he is chairing the department of Drug Design at the University of Groningen/The Netherlands. Dr. Dömling is founder of several biotech companies, including Morphochem and Carmolex. His research centers around the discovery of antagonists of protein- protein interactions and other biologically active compounds in the therapeutic areas of oncology, infectious and neglected tropical diseases using “out-of-the-box” software tools and multicomponent reaction chemistries. www.wiley-vch.de Edited by Alexander D€omling Protein–Protein Interactions in Drug Discovery Related Titles Methods and Principles in Medicinal Chemistry Edited by R. Mannhold, H. Kubinyi, G. Folkers Editorial Board H. Buschmann, H. Timmerman, H. van de Waterbeemd, T. Wieland Previous Volumes of this Series Kalgutkar, Amit S. / Dalvie, Deepak / De Clercq, Erik (Ed.) Obach, R. Scott / Smith, Dennis A. Antiviral Drug Strategies Reactive Drug Metabolites 2011 2012 ISBN: 978-3-527-32696-9, Vol. 50 ISBN: 978-3-527-33085-0, Vol. 55 Klebl, Bert / Muller,€ Gerhard / Hamacher, Brown, Nathan (Ed.) Michael (Eds.) Bioisosteres in Medicinal Protein Kinases as Drug Chemistry Targets 2012 2011 ISBN: 978-3-527-33015-7, Vol. 54 ISBN: 978-3-527-31790-5, Vol. 49 Gohlke, Holger (Ed.) Sotriffer, Christoph (Ed.) Protein-Ligand Interactions Virtual Screening 2012 Principles, Challenges, and Practical ISBN: 978-3-527-32966-3, Vol. 53 Guidelines 2011 Kappe, C. Oliver / Stadler, Alexander / ISBN: 978-3-527-32636-5, Vol. 48 Dallinger, Doris Microwaves in Organic and Rautio, Jarkko (Ed.) Medicinal Chemistry Prodrugs and Targeted Second, Completely Revised and Delivery Towards Better ADME Enlarged Edition Properties 2012 2011 ISBN: 978-3-527-33185-7, Vol. 52 ISBN: 978-3-527-32603-7, Vol. 47 Smith, Dennis A. / Allerton, Charlotte / Smit, Martine J. / Lira, Sergio A. / Leurs, Kalgutkar, Amit S. / van de Waterbeemd, Rob (Eds.) Han / Walker, Don K. Chemokine Receptors as Drug Pharmacokinetics and Targets Metabolism in Drug Design 2011 Third, Revised and Updated Edition ISBN: 978-3-527-32118-6, Vol. 46 2012 ISBN: 978-3-527-32954-0, Vol. 51 Edited by Alexander D€omling Protein–Protein Interactions in Drug Discovery Series Editors All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and Prof. Dr. Raimund Mannhold publisher do not warrant the information contained Molecular Drug Research Group in these books, including this book, to be free of Heinrich-Heine-Universit€at errors. Readers are advised to keep in mind that Universit€atsstrasse 1 statements, data, illustrations, procedural details or 40225 Dusseldorf€ other items may inadvertently be inaccurate. Germany Library of Congress Card No.: applied for [email protected] British Library Cataloguing-in-Publication Data Prof. Dr. Hugo Kubinyi A catalogue record for this book is available from the Donnersbergstrasse 9 British Library. 67256 Weisenheim am Sand Bibliographic information published by the Deutsche Germany Nationalbibliothek [email protected] The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; Prof. Dr. Gerd Folkers detailed bibliographic data are available on the Collegium Helveticum Internet at < http:// dnb.d-nb.d e> . STW/ETH Zurich 8092 Zurich # 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Switzerland Boschstr. 12, 69469 Weinheim, Germany [email protected] All rights reserved (including those of translation into other languages). No part of this book may be Volume Editor reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or Prof. Dr. Alexander D€omling translated into a machine language without written University of Groningen permission from the publishers. Registered names, School of Pharmacy trademarks, etc. used in this book, even when not Drug Design specifically marked as such, are not to be considered Antonius Deusinglaan 1 unprotected by law. 9713 AV Groningen Netherlands Composition Thomson Digital, Noida, India Printing and Binding Markono Print Media Pte Ltd, Cover Singapore Cut-away view of the co-crystal structure of an archetypical protein- protein interaction: the Cover Design Schulz Grafik-Design, Fugonheim€ tumor suppressor p53 and the oncogene Print ISBN: 978-3-527-33107-9 MDM2 (PDB ID 1YCR). The most deepest ePDF ISBN: 978-3-527-64823-8 buried p53 amino acid Trp23, anchoring the ePub ISBN: 978-3-527-64822-1 PPI, is shown in sticks presentation, the MDM2 mobi ISBN: 978-3-527-64821-4 receptor is shown as surface. Also shown the oBook ISBN: 978-3-527-64820-7 hydrogen bond between the Trp23 indole-NH and the receptor Leu54 carbonyl as green Printed in Singapore dotted line. The picture was rendered using Printed on acid-free paper PYMOL software. jV Contents List of Contributors XI Preface XV A Personal Foreword XVII 1 Protein–Protein Interactions: An Overview 1 Christian Ottman 1.1 Introduction 1 1.2 Role of PPIs in Human Physiology 2 1.3 Regulation of PPIs 3 1.4 Structural Features of PPI Interfaces 3 1.4.1 iNOS Homodimer 5 1.4.2 b-Catenin/Tcf4 Complex 5 1.4.3 LEDGF/HIV-IN Complex 6 1.4.4 HPV E1/E2 Complex 7 1.4.5 IFN-a/IFNAR Complex 8 1.4.6 TNF-a Trimer 9 1.5 Identification of PPI Inhibitors 10 1.6 Conclusions and Outlook 13 References 14 2 Prediction of Intra- and Interspecies Protein–Protein Interactions Facilitating Systems Biology Studies 21 Sylvia Schleker, Seshan Ananthasubramanian, Judith Klein-Seetharaman, and Madhavi K. Ganapathiraju 2.1 Introduction: Relevance of Interactome Studies to Disease and Drug Discovery 21 2.2 Our Current Knowledge of Interactomes Identified from Experiments is Incomplete 23 2.3 Reliability of Interactions Identified Experimentally 24 2.4 Computational Methods for PPI Prediction 27 2.4.1 Conservation of Gene Neighborhood 27 2.4.2 Gene Fusion 28 2.4.3 Sequence-Based Coevolution 28 VIj Contents 2.4.4 Phylogenetic Profiling 28 2.4.5 Gene Expression 29 2.4.6 Structural Similarity 29 2.4.7 Integration Approaches 29 2.5 Sources of Biological Data in Use to Predict PPIs 30 2.6 Survey of Current Interactomes 32 2.6.1 Human Intraspecies Interactomes 32 2.6.2 Bacteria Intraspecies Interactomes 37 2.6.2.1 High-Throughput Experimental Approaches to Identify Intraspecies Bacterial Interactions 37 2.6.2.2 Modeling Intraspecies Bacterial Interactions 39 2.6.3 Bacteria–Human Interspecies Interactomes 40 2.6.3.1 Experimental Approaches to Identify Bacteria–Human PPIs 40 2.6.3.2 Modeling Bacteria–Human PPIs 40 2.6.4 Non-PPI Intraspecies Bacterial and Bacteria–Human Interspecies Interactome Models 41 2.6.5 Virus–Human Interspecies Interactomes 42 References 43 3 Modulators of Protein–Protein Interactions: Importance of Three-Dimensionality 55 David C. Fry and Sung-Sau So 3.1 Introduction 55 3.2 Study 56 3.3 Discussion 58 3.4 Summary 61 References 61 4 A Leap into the Chemical Space of Protein–Protein Interaction Inhibitors 63 Bruno O. Villoutreix, C. Labbe, David Lagorce, Guillaume Laconde, and Olivier Sperandio 4.1 Introduction 63 4.2 Types of Interaction 64 4.3 Properties of the Interface 65 4.4 Orthosteric versus Allosteric Modulation 66 4.5 Leap into the iPPI Chemical Space 66 4.5.1 Seminal Works 66 4.5.2 Road to a Rationalization of the iPPI Chemical Space 67 4.6 Case Study 68 4.6.1 Visualizing the iPPI Chemical Space 70 4.6.2 iPPI versus ADME/Tox Properties 71 4.6.3 iPPI versus Aromaticity 75 4.6.4 iPPI versus Chemical Complexity 77 Contents jVII 4.6.5 iPPI versus Molecular Shape 77 4.6.6 iPPI versus Potency 79 4.7 Conclusions 80 References 81 5 Interactive Technologies for Leveraging the Known Chemistry of Anchor Residues to Disrupt Protein Interactions 85 Carlos J. Camacho, David R.
Load more

Recommended publications
  • 1 Randomized Trials of Retosiban Versus Placebo Or Atosiban In
    Randomized trials of retosiban versus placebo or atosiban in spontaneous preterm labor George Saade MDa, Andrew Shennan MDb, Kathleen J Beach MDc,1, Eran Hadar MDd, Barbara V Parilla MDe,2, Jerry Snidow PharmDf,3, Marcy Powell MDg, Timothy H Montague PhDh, Feng Liu PhDh,4, Yosuke Komatsu MDi,5, Laura McKain MDj,6, Steven Thornton DMk aDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA; bDepartment of Women and Children’s Health, King’s College London, St Thomas’ Hospital, London, UK; cDepartment of Maternal and Fetal Medicine, GSK, Research Triangle Park, NC, USA; dHelen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; eDepartment of Obstetrics and Gynecology, Advocate Lutheran General Hospital, Park Ridge, IL, USA; fAlternative Discovery and Development, GSK, Research Triangle Park, NC, USA; gCentral Safety Department, GSK, Research Triangle Park, NC, USA; hClinical Statistics, Quantitative Sciences, GSK, Collegeville, PA, USA; iMaternal and Neonatal Health Unit, Alternative Discovery & Development, R&D, GSK, Research Triangle Park, NC, USA; jPharmacovigilance, PPD, Wilmington, NC, USA; kBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK 1At the time of the trial; 2At the time of the trial, present address: Rush Center for Maternal- Fetal Medicine, Aurora, IL, USA; 3At the time of the trial; 4At the time of the trial, present address: AstraZeneca,
    [Show full text]
  • 1 the Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the 2 Response of Human Myometrial Explants to Prolonged Mechanical Stretch
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Apollo 1 The effect of an oxytocin receptor antagonist (retosiban, GSK221149A) on the 2 response of human myometrial explants to prolonged mechanical stretch. 3 4 Alexandros A. Moraitis, Yolande Cordeaux, D. Stephen Charnock-Jones, Gordon C. S. 5 Smith. 6 Department of Obstetrics and Gynaecology, University of Cambridge; NIHR Cambridge 7 Comprehensive Biomedical Research Centre, CB2 2SW, UK. 8 9 Abbreviated title: Retosiban and myometrial contractility. 10 Key terms: Retosiban, myometrial contractility, preterm birth, multiple pregnancy, oxytocin 11 receptor. 12 Word count: 2203 13 Number of figures: 3 14 15 Correspondending author and person to whom reprint requests should be addressed: 16 Gordon CS Smith. Department of Obstetrics and Gynaecology, University of Cambridge, 17 The Rosie Hospital, Cambridge, CB2 0SW, UK. 18 Tel: 01223 763888/763890; Fax: 01223 763889; 19 E-mail: [email protected] 20 21 Disclosure statement: 22 GS receives/has received research support from GE (supply of two diagnostic ultrasound 23 systems) and Roche (supply of equipment and reagents for biomarker studies). GS has 24 been paid to attend advisory boards by GSK and Roche. GS has acted as a paid consultant 25 to GSK. GS is named inventor in a patent submitted by GSK (UK), for the use of retosiban to 26 prevent preterm birth in multiple pregnancy (PCT/EP2014/062602), based on the work 27 described in this paper. GS and DSCJ have been awarded £199,413 to fund further 28 research on retosiban by GSK. AM has received a travel grant by GSK to present at the 1 29 Society of Reproductive Investigation (SRI) annual conference in March 2015.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Chapter 6 Industrial Applications of Multicomponent Reactions (Mcrs)
    University of Groningen Innovative multicomponent reactions and their use in medicinal chemistry Zarganes Tzitzikas, Tryfon IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2017 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Zarganes Tzitzikas, T. (2017). Innovative multicomponent reactions and their use in medicinal chemistry. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 CHAPTER 6 INDUSTRIAL APPLICATIONS OF MULTICOMPONENT REACTIONS (MCRS) Chapter contained in the Rodriguez-Bonne book Stereoselectve Multple Bond-Forming Transformatons in Organic Synthesis 2015 by John Wiley & Sons, Inc. Tryfon Zarganes – Tzitzikas, Ahmad Yazbak, Alexander Dömling Chapter 6 INTRODUCTION Multcomponent reactons (MCRs) can be defned as processes in which three or more reactants introduced simultaneously are combined through covalent bonds to form a single product, regardless of the mechanisms and protocols involved.[1] Many basic MCRs are name reactons, for example, Ugi,[2] Passerini,[3] van Leusen,[4] Strecker,[5] Hantzsch,[6] Biginelli,[7] or one of their many variatons.
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • FOGSI FOCUS PTL-Final
    Editors : President: Jaideep Malhotra Dr. Rishma Dhillon Pai Narendra Malhotra Contributors Preface Dr. Asha Reddy Dr. Ruchika Garg, Assistant Professor obs. & gynae, Dr. Apoorva Pallam Reddy, SN Medical College, Agra Consultant Preterm Labour is one of the 5 ‘P’ problem of pregnancy. Dr. Rajalaxmi Walavalkar, Dr. Anuradha Khar, Senior consultant, Cocoon fertility centre, Despite of understanding the problem, the prevalence is static Director, nurture IVF, Bangalore Thane even in developed countries. Dr. Arshi Iqbal, Dr. Raju Sahetya, Director Arshi fertility, Kota, Consultant obs. and gynae, Hinduja The problem of being born to soon is more in babies born Rajasthan Hospital, Mumbai before 33 weeks gestation and babies born in developing countries with low resource settings. Dr. Chaitanya Ganapule, Dr. Rakhi Singh, Pearl IVF, Pune Director Abalone clinic and IVF centre, Noida This multiauthored FOGSI focus is a comprehensive Dr. Kavita N Singh, collection of all aspects of Preterm Labour. The authors have Associate Professor, NSCB Medical Dr. Shalini Chauhan, done a great job in rehearsing each topic and compiling College, Jabalpur Assistant Professor, PGI Tanda relevant information which will be useful to the practising Dr. Kavitha Gautam, Dr. Seema Pandey, obstetrician. Director Bloom fertility, Chennai Director Seema Hospital and Eva fertility centre, Azamgarh Dr. Neema Acharya, We hope all FOGSIANS will benefit from this manuscript. Professor, DMIMS DU, Wardha Dr. Swati Upadhyay, SR KIMS, Trivendrum Dr. Niharika Malhotra Happy Reading Dr. Uma Pandey, Dr. Parul Mittal, specialist obs. & gynae, Professor obs. & gynae, IMS BHU, Aster D.M. Healthcare, Dubai, UAE Varanasi Jaideep Malhotra, Narendra Malhotra Dr. Paresh K Solanki Dr.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Molecular Basis of Ligand Recognition and Activation of Human V2 Vasopressin Receptor
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.18.427077; this version posted January 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular basis of ligand recognition and activation of human V2 vasopressin receptor Fulai Zhou1, 12, Chenyu Ye2, 12, Xiaomin Ma3, 12, Wanchao Yin1, Qingtong Zhou4, Xinheng He1, 5, Xiaokang Zhang6, 7, Tristan I. Croll8, Dehua Yang1, 5, 9, Peiyi Wang3, 10, H. Eric Xu1, 5, 11, Ming-Wei Wang1, 2, 4, 5, 9, 11, Yi Jiang1, 5, 1. The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China 2. School of Pharmacy, Fudan University, Shanghai 201203, China 3. Cryo-EM Centre, Southern University of Science and Technology, Shenzhen 515055, China 4. School of Basic Medical Sciences, Fudan University, Shanghai 200032, China 5. University of Chinese Academy of Sciences, 100049 Beijing, China 6. Interdisciplinary Center for Brain Information, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences; 7. Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China 8. Cambridge Institute for Medical Research, Department of Haematology, University of Cambridge, Cambridge, UK 9. The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China 10. Department of Biology, Southern University of Science and Technology, Shenzhen 515055, China 11. School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China 12. These authors contributed equally: Fulai Zhou, Chenyu Ye, and Xiaomin Ma.
    [Show full text]
  • Directed Evolution for High Functional Production and Stability of a Challenging G Protein‑Coupled Receptor Yann Waltenspühl, Jeliazko R
    www.nature.com/scientificreports OPEN Directed evolution for high functional production and stability of a challenging G protein‑coupled receptor Yann Waltenspühl, Jeliazko R. Jeliazkov, Lutz Kummer & Andreas Plückthun* Membrane proteins such as G protein‑coupled receptors (GPCRs) carry out many fundamental biological functions, are involved in a large number of physiological responses, and are thus important drug targets. To allow detailed biophysical and structural studies, most of these important receptors have to be engineered to overcome their poor intrinsic stability and low expression levels. However, those GPCRs with especially poor properties cannot be successfully optimised even with the current technologies. Here, we present an engineering strategy, based on the combination of three previously developed directed evolution methods, to improve the properties of particularly challenging GPCRs. Application of this novel combination approach enabled the successful selection for improved and crystallisable variants of the human oxytocin receptor, a GPCR with particularly low intrinsic production levels. To analyse the selection results and, in particular, compare the mutations enriched in diferent hosts, we developed a Next‑Generation Sequencing (NGS) strategy that combines long reads, covering the whole receptor, with exceptionally low error rates. This study thus gave insight into the evolution pressure on the same membrane protein in prokaryotes and eukaryotes. Our long‑ read NGS strategy provides a general methodology for the highly accurate analysis of libraries of point mutants during directed evolution. G protein-coupled receptors (GPCRs) play crucial roles in human physiology1,2. Tis biological importance is further refected in their therapeutic relevance. As such, GPCRs constitute the largest class of single drug targets, with an estimated 35% of marketed FDA approved drugs acting through these receptors3,4.
    [Show full text]
  • Oxytocin Receptor OXTR
    Oxytocin Receptor OXTR The oxytocin receptor belongs to the G-protein-coupled seven-transmembrane receptor superfamily. Its main physiological role is regulating the contraction of uterine smooth muscle at parturition and the ejection of milk from the lactating breast. The oxytocin receptors are activated in response to binding oxytocin and a similar nonapeptide, vasopressin. Oxytocin receptor triggers Gi or Gq protein-mediated signaling cascades leading to the regulation of a variety of neuroendocrine and cognitive functions. Oxytocin is a nonapeptide of the neurohypophyseal protein family that binds specifically to the oxytocin receptor to produce a multitude of central and peripheral physiological responses. In vivo, oxytocin acts as a paracrine and/or autocrine mediator of multiple biological effects. These effects are exerted primarily through interactions with G-protein-coupled oxytocin/vasopressin receptors, which, via Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides. www.MedChemExpress.com 1 Oxytocin Receptor Agonists & Antagonists Atosiban Atosiban acetate (RW22164; RWJ22164) Cat. No.: HY-17572 (RW22164 acetate; RWJ22164 acetate) Cat. No.: HY-17572A Atosiban (RW22164; RWJ22164) is a nonapeptide Atosiban acetate (RW22164 acetate;RWJ22164 competitive vasopressin/oxytocin receptor acetate) is a nonapeptide competitive antagonist, and is a desamino-oxytocin analogue. vasopressin/oxytocin receptor antagonist, and is a Atosiban is the main tocolytic agent and has the desamino-oxytocin analogue. Atosiban is the main potential for spontaneous preterm labor research. tocolytic agent and has the potential for spontaneous preterm labor research. Purity: 99.09% Purity: 99.92% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg Carbetocin Epelsiban Cat.
    [Show full text]
  • Leopold Dürrauer Masterarbeit Biologische Chemie
    MASTERARBEIT / MASTER’S THESIS Title der Masterarbeit / Title of the Master’s Thesis Characterisation of selective human oxytocin/ vasopressin ligands submitted by Leopold Dürrauer, BSc Angestrebter akademischer Grad / in partial fulfilment of the requirements for the degree of Master of Science (MSc) Wien, 2018 / Vienna, 2018 degree program code as it appears on A 066 863 the student record sheet: degree program as it appears on Biologische Chemie the student record sheet: Supervisor: Assoc. Prof. Priv.-Doz. Dr. Christian Gruber, PhD Masterarbeit Biologische Chemie ii Characterisation of selective human oxytocin/vasopressin ligands Acknowledgment I would like to thank Christian Gruber, for believing in me and providing me with the oppor- tunity to carry out this thesis on the other side of the globe. I would also like to thank Peter Keov for his invaluable practical support, Ester Aeiye Odukunle for sharing her asterotocin results, Markus Muttenthaler for synthesis of the peptides used dur- ing this thesis, and Yoonseong Park for his valuable insights into mite oxytocin/vasopressin- like peptide receptors. And, last but not least, I would like to thank my family and friends for their outstanding and unconditional support. 1 Masterarbeit Biologische Chemie 2 Masterarbeit Biologische Chemie Table of Contents Acknowledgment ....................................................................................................................... 1 Table of Contents ......................................................................................................................
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: April 2015 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 April 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]